Biontech strengthens manufacturing capabilities with first in-house plasmid dna manufacturing facility

Mainz, germany, february 2, 2023 – biontech se (nasdaq: bntx, “biontech” or “the company”) today announced construction completion of the company's first proprietary plasmid dna manufacturing facility in marburg, germany. plasmid dna is an important starting material for the manufacturing of mrna-based vaccines and therapies, as well as cell therapies. with the new facility, biontech plans to independently manufacture plasmid dna for clinical product candidates and commercial products in the areas of cancer and infectious diseases. german chancellor olaf scholz is visiting the new manufacturing facility in marburg today together with biontech co-founders prof. ugur sahin, m.d., chief executive officer, and prof. Özlem tÜreci, m.d., chief medical officer.
BNTX Ratings Summary
BNTX Quant Ranking